Digoxin

Generic Name: Digoxin

Brand Names: Digox, Lanoxin

Drug Type: Small Molecule

Chemical Formula: C_₄₁H_₆₄O_₁₄

CAS Number: 20830-75-5

Unique Ingredient Identifier: 73K4184T59

Background: Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.
...

Indication: Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.
...

Associated Conditions: Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure

Associated Therapies: -

Clinical Trials

Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of Digoxin Administered Alone and in Combination With Vandetanib

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Digoxin
Drug: Vandetanib

First Posted Date: 2012-03-23

Last Posted Date: 2016-08-29

Lead Sponsor: Sanofi

Target Recruit Count: 14

Registration Number: NCT01561781

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: liraglutide
Drug: placebo
Drug: atorvastatin
Drug: griseofulvin
Drug: lisinopril
Drug: digoxin

First Posted Date: 2012-01-25

Last Posted Date: 2017-01-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 70

Registration Number: NCT01518166

Locations: 🇸🇪
Novo Nordisk Investigational Site, Uppsala, Sweden

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: tivantinib
Drug: omeprazole
Drug: s-warfarin
Drug: caffeine
Dietary Supplement: vitamin K
Drug: digoxin
Drug: midazolam

First Posted Date: 2012-01-25

Last Posted Date: 2019-02-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 28

Registration Number: NCT01517399

Locations: 🇺🇸
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States

A Study to Investigate the Effect of YM150 on the Plasma Concentration of Digoxin in Healthy Subjects

Phase 1

Completed

Conditions: Healthy
Pharmacokinetic of Digoxin

Interventions: Drug: YM150
Drug: placebo
Drug: digoxin

First Posted Date: 2012-01-23

Last Posted Date: 2012-01-24

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 24

Registration Number: NCT01514812

A Drug-Drug Interaction Study of Digoxin and PA21

Phase 1

Completed

Conditions: Drug Interaction Potentiation

Interventions: Drug: PA21
Drug: Digoxin

First Posted Date: 2011-11-22

Last Posted Date: 2012-01-18

Lead Sponsor: Vifor Pharma

Target Recruit Count: 42

Registration Number: NCT01477411

Locations: 🇺🇸
ACRI - Phase 1, Anaheim, California, United States

A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Digoxin
Biological: Dulaglutide

First Posted Date: 2011-09-19

Last Posted Date: 2014-10-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT01436201

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States

Digoxin Withdrawal in Stable Heart Failure

Not Applicable

Completed

Conditions: Heart Failure

Interventions: Drug: Withdrawal of digoxin
Drug: Digoxin

First Posted Date: 2011-07-20

Last Posted Date: 2016-06-01

Lead Sponsor: The Alfred

Target Recruit Count: 16

Registration Number: NCT01398371

Locations: 🇦🇺
Clinical Pharmacology, Alfred Hospital, Melbourne, Victoria, Australia

A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: eliglustat; digoxin
Drug: digoxin

First Posted Date: 2011-05-23

Last Posted Date: 2015-03-23

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 28

Registration Number: NCT01357811

Locations: 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States

Effects of Administration of Fostamatinib on Blood Concentrations of Digoxin in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers
Rheumatoid Arthritis

Interventions: Drug: Digoxin
Drug: Fostamatinib

First Posted Date: 2011-05-18

Last Posted Date: 2011-10-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 21

Registration Number: NCT01355354

Locations: 🇬🇧
Research Site, London, United Kingdom

Drug Interaction Study of Digoxin and BI 10773

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Digoxin plus BI 10773
Drug: Digoxin

First Posted Date: 2011-03-01

Last Posted Date: 2014-06-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT01306175

Locations: 🇩🇪
1245.40.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy